Fungal Keratitis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Fungal Keratitis Market Outlook

Thelansis’s “Fungal Keratitis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Fungal Keratitis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Fungal Keratitis Overview

Fungal keratitis, also known as mycotic keratitis, presents a grave threat to vision. This severe condition often results in permanent blindness and loss of the affected eye. This corneal infection is notably destructive and is frequently associated with a poor prognosis, leading to substantial morbidity. It typically arises as a consequence of seemingly minor ocular trauma, with children accounting for approximately 4% of reported cases, though it predominantly affects adults aged 20–50 years. Various predisposing factors have been identified for filamentous fungal keratitis, including previous ocular surgery, ocular surface disease, contact lens usage, prior corticosteroid administration (either topically or systemically), and immunosuppressive conditions such as HIV/AIDS. Manifestations of keratitis often include abrupt onset of pain, sensitivity to light, discharge, and diminished vision, coupled with ocular inflammation and corneal opacity suggestive of an ulcer. Diagnosing and treating fungal keratitis frequently present significant challenges, particularly in regions with tropical or subtropical climates and high agricultural activity, where it constitutes a substantial proportion (23–63%) of all cases. Most patients exhibit at least one risk factor, with ocular surface disease, prior corneal surgery, and systemic immunosuppression being the most commonly reported. Presently, Natacyn® is the sole FDA-approved formulation for the treatment of fungal keratitis, consisting of a conventional natamycin suspension.

• Globally, fungal keratitis is the primary cause of corneal blindness, with an estimated incidence ranging from 2.5 to 27.6 per 100,000 population in the United States.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: